走进兰州，可以感受到这座老工业城市在嬗变。 一些企业家说，以前"跑断腿"的事，现在有政府专班人员在帮着跑，企业只专心做好生产经营；有科研 人员感慨，以前很多成果写完论文、评完奖就被束之高阁，现在转化的渠道更通畅了；有的干部坦言， 以前碰见棘手问题绕着走，现在不怕事、敢担事，还要琢磨如何干成事…… 这些心声被总结为一句话："当前的兰州呈现态势更好、气势更足、趋势更向上的发展势头。""十四 五"期间，特别是甘肃实施"强省会"行动以来的相关数据印证"兰州向上"—— 全市经济增速由2022年的0.8%提升至2025年的5.5%，对全省经济增长的贡献率由5.2%提升至27.7%；5 年来累计实施投资项目3270个，省外招商引资项目到位资金年均增长13%；综合科技进步水平指数达到 82.61%，跃居全球科研城市百强榜第48位；连续3年入选全国营商环境创新城市，连续4年居甘肃省营 商环境考评第一位。 近年来，兰州将营商环境视为"生命线"。甘肃省委常委、兰州市委书记张晓强说，对标国际国内一流水 平，兰州向高标准看齐，坚决打好优化营商环境攻坚战，着力营造良好产业发展生态和创业创新生态， 为推动高质量发展带来了新气象、新活力、新 ...

Core Insights - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that imposes a significant burden on patients, families, and society, necessitating a focus on controlling disease activity while minimizing long-term treatment risks [1][2] Group 1: Disease Characteristics - SLE is characterized by an immune system that mistakenly attacks the body's own tissues and organs, leading to diverse clinical manifestations [2] - Approximately 45% of SLE patients in China experience kidney involvement, and 37% have blood system abnormalities, with these rates being higher than in Western populations [2] - China has the highest number of SLE patients globally, predominantly affecting young women of childbearing age, with an average onset age of around 30 years [2] Group 2: Treatment Landscape - Historically, SLE treatment options were limited, primarily relying on steroids and immunosuppressants, leading to a "drug scarcity" situation for patients [3] - Long-term use of steroids can result in significant side effects, including obesity, osteoporosis, and elevated blood sugar levels, while immunosuppressants may increase infection risks [3] - The treatment strategy for SLE is shifting from "symptom control" to "long-term remission and organ protection," with the concept of "targeted therapy" emerging to maintain low disease activity or clinical remission [3] Group 3: Advances in Treatment - Recent advancements in treatment options, including biological agents, small molecule drugs, and cell therapies, have revolutionized SLE management [3] - Effective management of steroid use is crucial, as maintaining steroid levels without reduction equates to not achieving treatment goals [3] - The evolving treatment landscape aims to balance the reduction of steroid-related side effects with the risk of disease relapse during tapering [3]

Core Insights - AstraZeneca plans to invest over 100 billion RMB in China by 2030, focusing on cell therapy and radiolabeled drugs, marking a record for foreign pharmaceutical investments in the country [1][5] - The investment will primarily target Wuxi and Taizhou, with a strategic emphasis on these locations rather than spreading investments across multiple cities [1][5] Group 1: Investment Strategy - AstraZeneca's investment in Wuxi is significant as it has been the company's base in China since 1993, evolving into its largest production and packaging hub in the Asia-Pacific region [3][5] - Wuxi's established biopharmaceutical industry, with over 500 enterprises and a market size exceeding 200 billion RMB, provides a conducive environment for AstraZeneca's operations, reducing costs and improving efficiency [5][6] - The company aims to transform Wuxi into a leading digital pharmaceutical center, enhancing its global manufacturing network [5][6] Group 2: Regional Focus - In addition to Wuxi, AstraZeneca is investing in Taizhou, known for its strengths in vaccines and high-end formulations, with plans to expand its production capabilities in antibody-drug conjugates (ADCs) and monoclonal antibodies [7][9] - The Taizhou facility has already received significant investment and is positioned to support AstraZeneca's future growth in biopharmaceuticals, complementing Wuxi's small molecule drug production [9][10] - Qingdao is identified as a strategic point for AstraZeneca, focusing on inhalation aerosols and rare disease drugs, tapping into a growing market for rare diseases in China [10][11] Group 3: Financial Performance - AstraZeneca's revenue for 2024 is projected to reach approximately 54.07 billion USD, with a net profit of around 7.04 billion USD, indicating strong financial health to support its investment plans [15][20] - The Chinese market is crucial for AstraZeneca, contributing about 5.28 billion USD (approximately 37.5 billion RMB) in revenue for the first three quarters of 2025, making it the company's second-largest market globally [18][20] - The oncology segment has become a key revenue driver, accounting for 43% of total revenue in the first three quarters of 2025, reflecting a 16% year-on-year growth [16][17]

本报讯 "今年是封关首年，作为生物医药企业将持续创新，积极走向海外，把海南的生物医药创新成 果，通过自贸港政策'走出去'，走向全球。"省政协委员、海南苏生生物科技有限公司董事长、海南省 运动再生重点实验室主任曾胜表示，当前，海南正全力构建具有海南特色和优势的现代化产业体系，生 命健康产业迎来新的发展机遇。 "医产联动促进自贸港细胞医疗消费新增长。"曾胜希望，能设立"海口·乐城细胞治疗协同创新示范模 式"。由省发展改革委、卫健委等牵头，联动海口高新区和博鳌乐城，共建细胞治疗"研发-制备-应用-支 付"一体化模式。建立"乐城临床需求清单+海口技术供给清单"双向匹配机制，鼓励省内优质细胞研发机 构在乐城申报新技术应用，推动本地优质合规企业优先承接乐城备案新技术项目的制备任务。 曾胜提出，在已有生物医药产业政策基础上，增设细胞治疗研发及转化相关内容，对完成乐城应用的本 地企业给予奖励。探索纳入海南"惠民保"，提升可及性。突出细胞产业基金或投资方向，对生物新技术 转化提供资金助力。此外，打造面向国内外的高端医疗消费目的地。联动文旅、商务、外事等部门，推 出"细胞治疗+康养旅游"精品线路，将合规的细胞治疗项目纳入国际旅游 ...

Group 1 - AstraZeneca announced a significant investment plan of over 100 billion RMB (approximately 14 billion USD) in China by 2030, marking a record for foreign pharmaceutical companies in the country [1][2] - The investment aims to enhance AstraZeneca's drug production and research capabilities in China, reflecting the country's growing importance as a hub for scientific innovation and advanced manufacturing [2][5] - This strategic move is seen as a response to geopolitical tensions, emphasizing that healthy economic cooperation can stabilize international relations [2][5] Group 2 - The investment will cover the entire value chain from early drug discovery to large-scale production, with a focus on becoming the first multinational pharmaceutical company in China to have "end-to-end" cell therapy capabilities [2][5] - AstraZeneca's decision is driven by four unique advantages in China: a large and diverse patient population, a wealth of high-quality STEM talent, an encouraging regulatory environment, and a complete industrial chain [5] - The collaboration is expected to lead to the launch of 20 global innovative drugs in China by the end of 2030, improving access to cutting-edge treatments for patients [7][9] Group 3 - The investment signifies a shift in China's role from being merely an important market to a core strategic partner for multinational pharmaceutical companies [5] - AstraZeneca's commitment is anticipated to generate high-level technology and talent spillovers, enhancing China's position in the global pharmaceutical value chain [7] - The overarching message is that collaboration and openness are essential for addressing global challenges, with AstraZeneca's investment serving as a testament to the potential of working with China's innovative ecosystem [9]

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030, indicating a strategic shift in its global innovation focus, positioning China as a key node in its global innovation system [6][9]. Investment Strategy - The investment spans the entire value chain from drug discovery to commercialization, focusing on cutting-edge areas like cell therapy and radiolabeled drugs, which are characterized by high technical barriers and competition [6][7]. - AstraZeneca is not merely investing in traditional chemical or mature biologics but is betting on disruptive technology platforms that have the potential to reshape treatment paradigms [7]. Local Collaboration - AstraZeneca's strategy involves deep integration into China's innovation network through partnerships with local biotech firms, exchanging capital and global capabilities for early-stage innovative assets [8]. - The acquisition of Gensight Biologics in 2024 positions AstraZeneca as one of the few multinational companies with end-to-end cell therapy capabilities in China, which is strategically valuable amid rising global regulatory and supply chain uncertainties [8]. R&D and Clinical Trials - The global strategic R&D centers in Beijing and Shanghai are now leading global clinical trials, reflecting China's increasing influence in the global new drug development process [9]. - Collaborations with over 500 clinical hospitals enhance AstraZeneca's advantages in real-world data and patient recruitment efficiency [9]. Manufacturing Expansion - AstraZeneca's manufacturing bases in Wuxi, Taizhou, Qingdao, and Beijing are not only serving the Chinese market but are also supplying to over 70 global markets, indicating a shift from being a part of the global pharmaceutical supply chain to becoming a multi-regional drug export center [9]. - The establishment of a multi-center, switchable production system is part of AstraZeneca's risk management strategy in light of geopolitical and regulatory uncertainties [9]. Employment and Industry Impact - AstraZeneca's workforce in China is expected to exceed 20,000, creating high-value jobs in R&D, clinical, engineering, and quality systems, indicating a shift in the strategic position of local teams within the company [9]. - This investment aligns with China's "Healthy China 2030" goal, reflecting a complex market that offers both policy certainty and innovative returns for multinational pharmaceutical companies [9].

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific innovation and advanced manufacturing [2] Group 1: Investment Plans - The investment will enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline for cancer, blood diseases, and autoimmune diseases [3] - This investment follows a previous commitment of up to $2.5 billion to establish a strategic R&D center in Beijing, marking AstraZeneca's sixth global and second Chinese R&D center [2] Group 2: R&D and Innovation - As of January 2023, AstraZeneca has invested over $1.8 billion in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - The company currently has over 200 projects in its Chinese R&D pipeline, with 10-15 new projects added annually [3] Group 3: Strategic Importance - AstraZeneca's CEO emphasized that this investment marks a new chapter in the company's development in China, recognizing the country's role in scientific innovation and global public health [2]

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific and manufacturing strengths to deliver innovative therapies to patients globally [3][4]. Investment Plans - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, enhancing AstraZeneca's capabilities in cell therapy and radiolabeled drugs [4]. - This commitment follows a previous investment of up to 2.5 billion USD announced in March 2022 for establishing a strategic R&D center in Beijing, marking AstraZeneca's second such center in China [3]. R&D and Product Pipeline - Since 2023, AstraZeneca has invested over 1.8 billion USD to strengthen its manufacturing in China and plans to launch 20 global innovative drugs by the end of 2030 [4]. - As of January 2024, AstraZeneca's R&D pipeline in China includes over 200 projects, with 10-15 new projects added annually [4].

Group 1 - AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030 to expand its presence in drug production and R&D [1] - The investment aims to enhance the company's capabilities in cell therapy and radiolabeled drugs, benefiting patients with cancer, blood diseases, and autoimmune diseases [1] - The investment will deepen AstraZeneca's R&D presence in China, including global strategic R&D centers in Beijing and Shanghai, which collaborate with over 500 clinical hospitals [1] Group 2 - The company will upgrade its production bases in Wuxi, Taizhou, Qingdao, and Beijing, with plans to announce new production facilities [1] - Existing facilities are currently providing innovative medicines to patients in China and over 70 global markets [1] - The investment is expected to increase AstraZeneca's workforce in China to over 20,000 employees and create thousands of new jobs in the healthcare ecosystem [1]

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to enhance its drug production and R&D capabilities, leveraging China's scientific research strengths and advanced manufacturing [1][3] Group 1: Investment Details - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, aiming to bring China's innovative results to a global audience [3] - AstraZeneca's CEO highlighted that this investment marks a new chapter in the company's development in China, recognizing the country as a significant force in scientific innovation and global public health [3] Group 2: Strategic Initiatives - The investment will significantly enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline that benefits patients with cancer, blood diseases, and autoimmune disorders [3] - AstraZeneca aims to become the first multinational pharmaceutical company with end-to-end cell therapy capabilities in China [3] Group 3: Previous Investments - Since 2023, AstraZeneca has invested over 1.8 billion USD to strengthen its manufacturing in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - As of January this year, AstraZeneca's R&D pipeline in China includes over 200 projects, with 10-15 new projects added annually [3]